ArticleBlood cancer journal2024
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years.
Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Long-Term Results of Hematopoietic Cell Transplantation (HCT) for Adults with Blood Disorders- A Systematic Review.Stem cell reviews and reports · 2025Pooled it
- Trial
- Long-term Results of Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Real-life Data of 15- and 20-year Survivals from a Single Center.Stem cell reviews and reports · 2026Article
- Feasibility and outcomes of decentralized point-of-care CD19 CAR T cell for relapsed large B cell lymphoma in resource-limited settings.Molecular therapy. Oncology · 2026Article
- "Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL.Blood advances · 2026Article
- Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.Blood neoplasia · 2026Article
- The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).Bone marrow transplantation · 2026Article
- Impact of Bone Marrow Involvement on the Success of Hematopoietic Stem Cell Mobilization in Patients With Lymphoma.Cancer medicine · 2026Article
- Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.Blood advances · 2026Article
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
- Case Report: Surgical resection combined with chemotherapy for a primary cardiac lymphoma involving right heart structures.Frontiers in oncology · 2026Article
- ATF6 and pS6K as prognostic biomarkers in newly diagnosed diffuse large B-cell lymphoma.Scientific reports · 2025Article
- ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling.Bone marrow transplantation · 2025Article
- Article
- miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma.Journal of translational medicine · 2025Article
- Advancement of bottom-up precipitation synthesis and applications of barium sulphate nanoparticles.RSC advances · 2025Review
- Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.JCO precision oncology · 2025Article
- Long-term follow-up of autologous hematopoietic cell transplantation for diffuse large B cell lymphoma in the rituximab era: real‑world data from a retrospective single‑center analysis.Annals of hematology · 2025Article
- Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report.Hematology reports · 2025Article
- Navigating CAR-T cell therapy long-term complications.Nature cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous(auto-) and allogeneic(allo-) hematopoietic stem cell transplantation (HSCT) are key treatments for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), although their roles are challenged by CAR-T-cells and other immunotherapies. We examined the transplantation trends and outcomes for DLBCL patients undergoing auto-/allo-HSCT between 1990 and 2021 reported to EBMT. Over this period, 41,148 patients underwent auto-HSCT, peaking at 1911 cases in 2016, while allo-HSCT saw a maximum of 294 cases in 2018. The recent decline in transplants corresponds to increased CAR-T treatments (1117 cases in 2021). Median age for auto-HSCT rose from 42 (1990-1994) to 58 years (2015-2021), with peripheral blood becoming the primary stem cell source post-1994. Allo-HSCT median age increased from 36 (1990-1994) to 54 (2015-2021) years, with mobilized blood as the primary source post-1998 and reduced intensity conditioning post-2000. Unrelated and mismatched allo-HSCT accounted for 50% and 19% of allo-HSCT in 2015-2021. Three-year overall survival (OS) after auto-HSCT improved from 56% (1990-1994) to 70% (2015-2021), p < 0.001, with a decrease in relapse incidence (RI) from 49% to 38%, while non-relapse mortality (NRM) remained unchanged (4%). After allo-HSCT, 3-year-OS increased from 33% (1990-1999) to 46% (2015-2021) (p < 0.001); 3-year RI remained at 39% and 1-year-NRM decreased to 19% (p < 0.001). Our data reflect advancements over 32 years and >40,000 transplants, providing insights for evaluating emerging DLBCL therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.